ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$4.24
-0.13 (-2.97%)
Open$4.36
Previous Close$4.37
Day High$4.42
Day Low$4.18
52W High$5.10
52W Low$2.71
Volume—
Avg Volume3.22M
Market Cap903.92M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,108.7% upside
Current
$4.24
$4.24
Target
$51.25
$51.25
$34.47
$51.25 avg
$59.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.09M | 8.60M | 146.67M |
| Net Income | -80,498,287 | -87,816,313 | -16,611,843 |
| Profit Margin | -1,133.0% | -1,076.4% | -11.3% |
| EBITDA | -86,268,008 | -99,338,918 | -23,689,130 |
| Free Cash Flow | — | — | -19,958,595 |
| Rev Growth | -17.5% | -17.5% | -8.1% |
| Debt/Equity | 0.05 | 0.05 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |